JaLCDOI 10.18926/AMO/56464
FullText URL 73_1_85.pdf
Author Abe, Yoshiyuki| Fujibayashi, Kazutoshi| Nishizaki, Yuji| Yanagisawa, Naotake| Nojiri, Shuko| Nakano, Soichiro| Tada, Kurisu| Yamaji, Ken| Tamura, Naoto|
Abstract Pneumocystis pneumonia (PCP) due to Pneumocystis jirovecii infection is the leading cause of fatal opportunistic infections in immunocompromised patients. We will determine whether a daily sulfamethoxazole-trimethoprim (SMX/TMP) dose of 200/40 mg was non-inferior to 400/80 mg for PCP prevention in patients with systemic rheumatic disease under immunosuppressive therapy. This is a randomized, open-label, multicenter controlled trial. The primary outcome is the rate of PCP prevention at 52 weeks. The secondary outcome is the discontinuation rate of SMX/TMP. The trial will evaluate the optimal dose of SMX/TMP for PCP prevention in patients with systemic rheumatic disease under immunosuppressive therapy.
Keywords pneumocystis pneumonia prophylaxis systemic rheumatic disease sulfamethoxazole-trimethoprim conventional-dose versus half-dose
Amo Type Clinical Study Protocol
Published Date 2019-02
Publication Title Acta Medica Okayama
Volume volume73
Issue issue1
Publisher Okayama University Medical School
Start Page 85
End Page 89
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2019 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 30820060